stockportfolio.pro
Stocks / ARGX vs REGN
ARGX vs REGN
argenx SE and Regeneron Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| argenx SE (ARGX) | Regeneron Pharmaceuticals, Inc. (REGN) | |
|---|---|---|
| Market cap | $55.7B | $64.6B |
| Revenue (latest FY) | $4.15B | $14.34B |
| Net income (latest FY) | $1.29B | $4.50B |
| Revenue growth (5y CAGR) | 116.2% | 11.0% |
| Net margin | 31.1% | 31.4% |
| Return on equity | 17.6% | 14.4% |
| P/E ratio | 39.6 | 15.0 |
| Dividend yield | — | 0.6% |
| Profitable years (of last 10) | 2 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ARGX — free Open REGN — freeFrequently asked questions
Which is bigger, ARGX or REGN?
Regeneron Pharmaceuticals, Inc. is larger by market capitalization — $64.6B versus $55.7B.
Which grows faster, ARGX or REGN?
Over the last five fiscal years, argenx SE grew revenue faster — 116.2%/yr versus 11.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.